JDRF and ViaCyte share a continuing commitment to realizing the potential of
beta cell replacement strategies to deliver insulin independence without immune suppression for people living with type 1 diabetes, and ultimately, at JDRF we hope this will move us forward in fulfilling our vision of a world without type 1 diabetes.»
«JDRF remains dedicated to accelerating the delivery of
beta cell replacement therapies to the T1D community, and we commend ViaCyte in its announcement of the first patients to be implanted with the PEC - Direct islet cell replacement therapy,» said Derek Rapp, JDRF President and Chief Executive Officer.
STEP ONE is the first trial in the world investigating a stem cell - derived
beta cell replacement therapy for diabetes.
Our group is specifically working on improvement of islet isolation and transplantation protocols in clinical practice and the development of novel therapeutic options in the field of
beta cell replacement with a clear translational «bench to bedside» approach by linking experimental research with preclinical and clinical work:
Other researchers at Joslin are conducting large scale genetic screening for novel therapeutic targets to control autoimmunity, which will complement the effort of BAIRT to extend autologous
beta cell replacement to patients with type 1 diabetes.
With these findings, Helmholtz Zentrum München scientists have discovered key molecular functions of stem cell differentiation which could be used for
beta cell replacement therapy in diabetes.
The goal was to generate functional beta - like cells from pancreatic alpha cells, which may be the ideal source for
beta cell replacement.
Not exact matches
By flipping on three key genes in
cells from the lower stomach, scientists may have engineered a viable
replacement for those
beta cells.
But in patients with type 1 diabetes,
beta -
cell replacement therapy is likely doomed to failure because the new
cells might fall victim to the same autoimmunity that destroyed the original
cells.
An EU - funded research project («HumEn»), in which Lickert and his team are participating, shall provide further insights in the field of
beta -
cell replacement therapy.
«The loss of insulin - producing
beta cells leads to type 1 diabetes, making it an ideal target for
cell replacement therapy,» said James Shapiro, MD, PhD, FRCSC, Director of the Clinical Islet Transplant Program, University of Alberta.
A permanent solution —
beta -
cell replacement — has long been the goal of stem
cell scientists.
Additionally, researchers found that Smed -
beta - catenin - 1 plays a role in ongoing
cell replacement in planaria that have not been challenged to regenerate.
In addition, we use our expertise to facilitate the development of functionally mature
beta cells from embryonic stem
cells for
cell replacement therapies of type 1 diabetes.
Partial clinical hold on high dose SGT - 001 resolved, additional information requested on full clinical hold NIH grant will further development of
replacement beta cells for type 1 and type 2 diabetes New trial will assess MSCs to improve heart function in heart failure patients ReNeuron wins grant for retinal
cell therapy development
Animal trials have shown that the
replacement cells successfully duplicate the function of the insulin - producing
beta cells.
The VC - 01 product candidate is the first embryonic stem
cell - derived islet
replacement therapy to reach clinical testing and is currently being evaluated in patients with T1D who have minimal to no insulin - producing
beta cell function.
Recent leaps forward in these technologies make this a very promising avenue for generating large numbers of
replacement beta cells.
Researchers are looking at ways to restore the number of functional
beta cells in patients with diabetes, pursuing both the
replacement of lost
beta cells and the protection of
beta cells from further damage.
The following compounds have been demonstrated experimentally to regenerate the insulin - producing
beta cells, which are destroyed in insulin dependent diabetes, and which once restored, may (at least in theory) restore the health of the patient to the point where they no longer require insulin
replacement.